Cases 31 - 40 of 404
Actelion Pharmaceuticals Ltd v. Mylan Pharmaceuticals Inc.
as 22-1889
Plaintiff / Appellee:
ACTELION PHARMACEUTICALS, LTD.
Defendant / Appellant:
MYLAN PHARMACEUTICALS INC.
MOMENTA PHARMACEUTICALS, INC. v. MYLAN PHARMACEUTICALS, INC. et al
as 2:2022cv00750
Plaintiff:
MOMENTA PHARMACEUTICALS, INC.
Defendant:
MYLAN PHARMACEUTICALS, INC., MYLAN, INC., VIATRIS, INC. and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
AstraZeneca AB et al v. Mylan Pharmaceuticals Inc. et al
as 1:2022cv00035
Plaintiff:
AstraZeneca AB and Astrazeneca Pharmaceuticals LP
Defendant:
Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Otsuka Pharmaceutical Co., Ltd. et al v. Mylan Laboratories Limited et al
as 1:2022cv00464
Plaintiff:
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S
Defendant:
Mylan Laboratories Limited, Viatris Inc. and Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Otsuka Pharmaceutical Co., Ltd. et al v. Mylan Laboratories Limited et al
as 1:2022cv00032
Plaintiff:
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S
Defendant:
Mylan Laboratories Limited, Viatris Inc. and Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. et al
as 1:2022cv00451
Plaintiff:
Novartis Pharmaceuticals Corporation
Defendant:
Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Novo Nordisk, Inc. et al v. Mylan Pharmaceuticals, Inc.
as 1:2022cv00023
Counter Defendant:
Novo Nordisk, Inc. and Novo Nordisk, A/S
Defendant:
Mylan Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
BAUSCH HEALTH IRELAND LIMITED et al v. MYLAN LABORATORIES LTD. et al
as 1:2022cv00020
Plaintiff:
Bausch Health Ireland Limited and Salix Pharmaceuticals, Inc
Defendant:
Mylan Laboratories Ltd., Agila Specialties Inc., Mylan API US LLC and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. et al
as 1:2021cv00146
Plaintiff:
Novartis Pharmaceuticals Corporation
Defendant:
Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited and others
Cause Of Action: 35 U.S.C. § 271
In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation
as 1:2021md03017
In Re:
Xarelto (Rivaroxaban) ('310) Patent Litigation
Not Classified By Court:
Clerk of MDL Panel, Lupin Limited, Lupin Pharmaceuticals, Inc. and others
Counter Defendant:
Bayer Pharma AG, Bayer AG and Janssen Pharmaceuticals, Inc.
Defendant:
ScieGen Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
